Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Receivables: 2020-2024

Historic Receivables for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $48.7 million.

  • Oncology Institute's Receivables rose 932.92% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year increase of 932.92%. This contributed to the annual value of $48.7 million for FY2024, which is 1344.64% up from last year.
  • Oncology Institute's Receivables amounted to $48.7 million in FY2024, which was up 1344.64% from $42.9 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Receivables ranged from a high of $48.7 million in FY2024 and a low of $17.3 million during FY2020
  • Over the past 5 years, Oncology Institute's median Receivables value was $40.4 million (recorded in 2022), while the average stood at $34.1 million.
  • Its Receivables has fluctuated over the past 5 years, first soared by 9032.67% in 2022, then surged by 612.87% in 2023.
  • Over the past 5 years, Oncology Institute's Receivables (Annual) stood at $17.3 million in 2020, then increased by 23.09% to $21.2 million in 2021, then surged by 90.33% to $40.4 million in 2022, then grew by 6.13% to $42.9 million in 2023, then grew by 13.45% to $48.7 million in 2024.
  • Its Receivables stands at $48.7 million for FY2024, versus $42.9 million for FY2023 and $40.4 million for FY2022.